Grupo Dermatologico Y Estetico Pedro Jaen S.A.

Madrid 17 trials 5 recruiting

17 Registered trials

5 Currently recruiting

Organisation

Grupo Dermatologico Y Estetico Pedro Jaen S.A.

Location

Madrid, Spain

Identifier

ORG-100043486

Address

Calle De Serrano 143, 28006, Spain

Departments

#7502: Servicio Dermatología
40888: Dermatología
9255: Servicio Dermatología
Cantero
Dermatología
Dermatology
Grupo Dermatologico y Estetico Pedro Jaen
na

Clinical trials at this site (17)

Search interface

A Phase 4 Mechanistic Longitudinal Study to Evaluate the Impact of EARLY Risankizumab Treatment on TRM Cell Levels in Moderate-to-Severe Pso… Pending

2025-521424-30-00 Psoriasis 6
A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting

2024-520337-80-00 Palmoplantar Pustulosis 5 2026-01-07
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Ato… Recruiting

2022-501478-21-00 Atopic Dermatitis Eczema 5 2024-03-15
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A Study Evaluating BFB759 in Atopic Dermatitis Ended

2025-521624-30-00 Atopic dermatitis 4 2026-01-08
A Study of Two Doses of Ritlecitinib in People 12 Years of Age and Older with Alopecia Areata Ended

2024-519370-40-00 Alopecia areata 5 2025-07-16
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513266-19-00 Hidradenitis Suppurativa (HS) 5 2025-06-13
Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended

2023-503383-17-01 Female androgenetic alopecia 5 2024-10-10
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505120-59-00 Moderate to Severe Plaque Psoriasis 5 2023-12-19
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of… Ended

2024-517814-13-00 Moderate to Severe Atopic Dermatitis 4 2025-04-30
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511363-28-00 hidradenitis suppurativa (HS) 5 2024-09-24
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Parti… Ended

2022-500568-37-00 Masseter Muscle Prominence 5 2023-10-11
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended

2022-501476-25-00 Atopic Dermatitis Eczema 5 2023-09-12
A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoria… Ended

2023-508992-35-00 Plaque Psoriasis 4